diphenylamine has been researched along with mk 2206 in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goldberg, GL; Hazan, R; Horwitz, SB; Hou, JY; McDaid, HM; Rodriguez-Gabin, A; Samaraweera, L; Samaweera, L | 1 |
| Glassmann, A; Kraus, D; Probstmeier, R; Veit, N; Winter, J | 1 |
| Chinn, DC; Gandara, DR; Holland, WS; Lara, PN; Mack, PC | 1 |
| Wu, CH; Wu, X; Zhang, HW | 1 |
4 other study(ies) available for diphenylamine and mk 2206
| Article | Year |
|---|---|
Exploiting MEK inhibitor-mediated activation of ERĪ± for therapeutic intervention in ER-positive ovarian carcinoma.
Topics: Animals; Antineoplastic Agents, Hormonal; Benzamides; Carcinoma; Cell Line, Tumor; Diphenylamine; Estradiol; Estrogen Receptor alpha; Extracellular Signal-Regulated MAP Kinases; Feedback, Physiological; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; Lapatinib; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Ovarian Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
Pharmacological suppression of the Ras/MAPK pathway in thyroid carcinoma cells can provoke opposite effects on cell migration and proliferation: The appearance of yin-yang effects and the need of combinatorial treatments.
Topics: Benzamides; Carcinoma; Carcinoma, Papillary; Cell Line, Tumor; Cell Movement; Cell Proliferation; Diphenylamine; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; MAP Kinase Signaling System; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Thyroid Cancer, Papillary; Thyroid Neoplasms; Yin-Yang | 2014 |
Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines.
Topics: Apoptosis; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diphenylamine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Hepatocyte Growth Factor; Heterocyclic Compounds, 3-Ring; Humans; Immunoblotting; Lung Neoplasms; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; ras Proteins | 2015 |
Inhibition of acquired-resistance hepatocellular carcinoma cell growth by combining sorafenib with phosphoinositide 3-kinase and rat sarcoma inhibitor.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diphenylamine; Drug Resistance, Neoplasm; Heterocyclic Compounds, 3-Ring; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2016 |